Miragen Therapeutics, Inc. (MGEN) Forecasted to Earn Q1 2019 Earnings of ($0.29) Per Share

Miragen Therapeutics, Inc. (NASDAQ:MGEN) – Analysts at B. Riley issued their Q1 2019 earnings per share estimates for shares of Miragen Therapeutics in a research report issued on Thursday, March 15th, Zacks Investment Research reports. B. Riley analyst M. Kumar expects that the medical research company will earn ($0.29) per share for the quarter. B. Riley has a “Buy” rating and a $15.50 price objective on the stock. B. Riley also issued estimates for Miragen Therapeutics’ Q2 2019 earnings at ($0.28) EPS, Q3 2019 earnings at ($0.27) EPS and Q4 2019 earnings at ($0.26) EPS.

How to Become a New Pot Stock Millionaire

Miragen Therapeutics (NASDAQ:MGEN) last released its earnings results on Wednesday, March 14th. The medical research company reported ($0.29) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.33) by $0.04. Miragen Therapeutics had a negative return on equity of 63.57% and a negative net margin of 662.30%. The firm had revenue of $1.19 million during the quarter, compared to the consensus estimate of $1.22 million.

MGEN has been the subject of a number of other research reports. Oppenheimer assumed coverage on Miragen Therapeutics in a report on Friday, January 12th. They set an “outperform” rating and a $13.00 target price for the company. Wedbush reaffirmed an “outperform” rating and set a $19.00 target price on shares of Miragen Therapeutics in a report on Wednesday, March 28th. Chardan Capital reaffirmed a “buy” rating on shares of Miragen Therapeutics in a report on Tuesday, January 16th. Cann assumed coverage on Miragen Therapeutics in a report on Friday, January 12th. They set an “outperform” rating and a $13.00 target price for the company. Finally, Deutsche Bank started coverage on Miragen Therapeutics in a report on Thursday, March 22nd. They set a “buy” rating and a $15.00 target price for the company. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the stock. Miragen Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $16.31.

Shares of Miragen Therapeutics stock traded down $0.37 on Friday, reaching $6.50. 219,209 shares of the stock were exchanged, compared to its average volume of 380,594. The company has a quick ratio of 13.33, a current ratio of 13.33 and a debt-to-equity ratio of 0.26. Miragen Therapeutics has a twelve month low of $5.01 and a twelve month high of $15.91. The company has a market capitalization of $207.28, a price-to-earnings ratio of -4.71 and a beta of 1.33.

Institutional investors have recently bought and sold shares of the company. Virtu Financial LLC increased its position in shares of Miragen Therapeutics by 372.8% in the fourth quarter. Virtu Financial LLC now owns 51,896 shares of the medical research company’s stock valued at $541,000 after buying an additional 40,920 shares in the last quarter. SG Americas Securities LLC purchased a new stake in shares of Miragen Therapeutics in the third quarter valued at approximately $250,000. Seaward Management Limited Partnership purchased a new stake in shares of Miragen Therapeutics in the third quarter valued at approximately $117,000. Aveo Capital Partners LLC purchased a new stake in shares of Miragen Therapeutics in the fourth quarter valued at approximately $279,000. Finally, Russell Investments Group Ltd. purchased a new stake in shares of Miragen Therapeutics in the third quarter valued at approximately $147,000. Institutional investors and hedge funds own 18.98% of the company’s stock.

In related news, Director Bruce Booth purchased 545,454 shares of the firm’s stock in a transaction on Tuesday, February 13th. The stock was bought at an average cost of $5.50 per share, with a total value of $2,999,997.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Adam Scott Levy purchased 9,090 shares of the firm’s stock in a transaction on Tuesday, February 13th. The stock was bought at an average cost of $5.50 per share, with a total value of $49,995.00. Following the completion of the acquisition, the insider now directly owns 10,540 shares of the company’s stock, valued at approximately $57,970. The disclosure for this purchase can be found here. Insiders own 44.40% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Miragen Therapeutics, Inc. (MGEN) Forecasted to Earn Q1 2019 Earnings of ($0.29) Per Share” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/04/08/miragen-therapeutics-inc-mgen-forecasted-to-earn-q1-2019-earnings-of-0-29-per-share.html.

Miragen Therapeutics Company Profile

Signal Genetics, Inc is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company’s diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test.

Get a free copy of the Zacks research report on Miragen Therapeutics (MGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Miragen Therapeutics (NASDAQ:MGEN)

Receive News & Ratings for Miragen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Miragen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply